Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Zanubrutinib is Well Tolerated and Effective in Acalabrutinib-Intolerant Patients with B-cell Malignancies

Mazyar Shadman, Ian W. Flinn, Moshe Y. Levy, Benjamin B. Freeman, Ben Zhang, John M. Burke, Jennifer L. Cultrera, Habte A. Yimer, Edwin C. Kingsley, Charles M. Farber, James D'Olimpio, Hui Yao, Adam Idoine, Qi An, Jeff P. Sharman

Blood (2024) 144 (Supplement 1): 4632.

https://doi.org/10.1182/blood-2024-198250

Published: 2024

Journal Articles

Outcomes of Children and Adolescents with Acute Myeloid Leukemia and KIT Mutations Treated with Low- or Standard-Dose Chemotherapy Plus Dasatinib on the CALSⅢ-AML18 Trial

Yixin Hu, Xiuli Ju, Yunyan He, Ningling Wang, Xiaowen Zhai, Yufeng Liu, Hua Jiang, Hongjun Liu, Liangchun Yang, Minghua Yang, Jixia Luo, Qi An, Xiaojun Yuan, Qian-Fei Wang, Raul C. Ribeiro, Shaoyan Hu

Blood (2024) 144 (Supplement 1): 6050.

https://doi.org/10.1182/blood-2024-211911

Published: 2024

Journal Articles

Outcomes of Children and Adolescents with Acute Myeloid Leukemia and FLT3-ITD Treated with Low- or Standard-Dose Chemotherapy Plus Sorafenib on the Cals III-AML18 Trial (ChiCTR1800015883)

Li Gao, Hua Jiang, Xiuli Ju, Yunyan He, Hongjun Liu, Xiaowen Zhai, Ningling Wang, Minghua Yang, Jixia Luo, Yufeng Liu, Liangchun Yang, Qi An, Xiaojun Yuan, Qian-Fei Wang, Raul C. Ribeiro, Shaoyan Hu

Blood (2024) 144 (Supplement 1): 6049.

https://doi.org/10.1182/blood-2024-211113

Published: 2024

Journal Articles

Outcomes of Children and Adolescents with Acute Myeloid Leukemia Given a Low-Versus Standard-Dose Chemotherapy Regimen for Remission Induction (CALSIII-AML18): A Multicenter, Phase 3, Randomized, Noninferiority Trial

Blood (2023) 142 (Supplement 1): 729.

https://doi.org/10.1182/blood-2023-189253

Published: 2023

Journal Articles

A Multicenter Clinical Study with Reduced Intensive Chemotherapy for Induction Remission of Pediatric Acute Megakaryoblastic Leukemia

Blood (2023) 142 (Supplement 1): 4276.

https://doi.org/10.1182/blood-2023-190821

Published: 2023

Journal Articles

A Phase I/Pilot Study of CPX-351 [Daunorubicin and Cytarabine Liposome for Injection (Vyxeos®)] for Children, Adolescents and Young Adults with Recurrent or Refractory Acute Leukemia

Michael J. Absalon, MD PhD, Erin H. Breese, MD PhD, Lynn Lee, MD, Maureen M O'Brien, MD MS, Christine L Phillips, MD, Karen Burns, MD, Benjamin Mizukawa, MD, Qi An, Jennifer Mangino, MD, Joel Kaplan, DO, Robin Norris, MD, John Peter Perentesis, MD

Blood (2018) 132 (Supplement 1): 336.

https://doi.org/10.1182/blood-2018-99-119618

Published: 2018

Journal Articles

Final Safety and Efficacy Results from the CPX-351 Early Access Program (EAP) for Older Patients with High-Risk/Secondary Acute Myeloid Leukemia (sAML)

Gail J. Roboz, MD, Melissa L. Larson, MD, S. Eric Rubenstein, MD, Scott R Solomon, MD, Gary J. Schiller, MD, Qi An, Emaryn Mancino, Michael Chiarella, Arthur C. Louie, Tara L Lin, MD

Blood (2018) 132 (Supplement 1): 1434.

https://doi.org/10.1182/blood-2018-99-111537

Published: 2018

Journal Articles

Subanalysis of Patients with Secondary Acute Myeloid Leukemia (sAML) with Refractory Anemia with Excess of Blasts in Transformation (RAEB-t) Enrolled in a Phase 3 Study of CPX-351 Versus Conventional 7+3 Cytarabine and Daunorubicin

Tara L. Lin, MD, Geoffrey L. Uy, MD, Matthew J. Wieduwilt, Laura F. Newell, MD, Robert K. Stuart, MD, Bruno C Medeiros, MD, Gary J. Schiller, Eric Rubenstein, MD, Wendy Stock, MD, Erica D. Warlick, MD, Matthew Foster, Dale L. Bixby, Nikolai A. Podoltsev, MD PhD, Qi An, Stefan Faderl, Arthur C. Louie, Jeffrey E. Lancet, MD

Blood (2017) 130 (Supplement 1): 1698.

https://doi.org/10.1182/blood.V130.Suppl_1.1698.1698

Published: 2017

Journal Articles

Hemophagocytic Lymphohistiocytosis (HLH) in Langerhans Cell Histiocytosis (LCH): A Multicenter Retrospective Descriptional Study

Deepak Chellapandian, MD MBBS, Rui Zhang, MD, Michael Jeng, MD, Cor Van Den Bos, MD PhD, Vicente Santa-María López, MD, Kai Lehmberg, MD, Elena Sieni, MD, Yini Wang, MD, Taizo Allen Nakano, MD, James Williams, MD, Nicholas J. Fustino, MD, Itziar Astigarraga, MD, Ira Dunkel, MD, Qi An, Cheng Cheng, PhD, Sheila Weitzman, MB BCh, FRCP, Lillian Sung, MD PhD, Kim E. Nichols, MD

Blood (2016) 128 (22): 707.

https://doi.org/10.1182/blood.V128.22.707.707

Published: 2016

Journal Articles

Targeted Inhibition of the MLL Transcriptional Complex By Proteosome Inhibitors Elicits a High Response Rate in Relapsed/Refractory MLL Rearranged Leukemia

Cary Koss, BS, Stephanie Nance, PhD, Michele Connelly, MS, Jing Ma, PhD, Anang Shelat, PhD, Anitria Cotton, BS, Qi An, MS, Cheng Cheng, PhD, Monika L. Metzger, MD MS, Sima Jeha, MD, Jeffrey E Rubnitz, MD PhD, James R Downing, MD, R. Kiplin Guy, PhD, Tanja A Gruber, MD PhD

Blood (2014) 124 (21): 972.

https://doi.org/10.1182/blood.V124.21.972.972

Published: 2014

Journal Articles

Outcomes after Intermediate-Risk Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL) and the Role of Allogeneic Stem Cell Transplantation (SCT): A Report from Children's Oncology Group (COG) AALL0433

Glen Lew, MD, Xiaomin Lu, PhD, Rochelle Yanofsky, MD FRCP(C), Susan R. Rheingold, MD, James Whitlock, Qi An, Meenakshi Devidas, PhD, Caroline A. Hastings, MD, Naomi J. Winick, MD, William L. Carroll, MD, Michael J. Borowitz, MD PhD, Stephen Hunger, MD, Michael A. Pulsipher, MD

Blood (2014) 124 (21): 684.

https://doi.org/10.1182/blood.V124.21.684.684

Published: 2014

Journal Articles

Clinical and Laboratory Factors Influencing The Probability Of Complete Remission In AML Patients With Positive Day 14 Bone Marrows

Maxim Norkin, MD, PhD, Jan Moreb, MD, Helen Leather, BPharm, Randy A. Brown, MD, Jack W. Hsu, MD, John W Hiemenz, MD, W. Stratford May, MD, PhD, Myron N Chang, PhD, Qi An, Ying Li, MD, PhD, Christopher R Cogle, MD, John R Wingard, MD

Blood (2013) 122 (21): 1412.

https://doi.org/10.1182/blood.V122.21.1412.1412

Published: 2013

NARROW

Zanubrutinib is Well Tolerated and Effective in Acalabrutinib-Intolerant Patients with B-cell Malignancies

Outcomes of Children and Adolescents with Acute Myeloid Leukemia and KIT Mutations Treated with Low- or Standard-Dose Chemotherapy Plus Dasatinib on the CALSⅢ-AML18 Trial

Outcomes of Children and Adolescents with Acute Myeloid Leukemia and FLT3-ITD Treated with Low- or Standard-Dose Chemotherapy Plus Sorafenib on the Cals III-AML18 Trial (ChiCTR1800015883)

Outcomes of Children and Adolescents with Acute Myeloid Leukemia Given a Low-Versus Standard-Dose Chemotherapy Regimen for Remission Induction (CALSIII-AML18): A Multicenter, Phase 3, Randomized, Noninferiority Trial

A Multicenter Clinical Study with Reduced Intensive Chemotherapy for Induction Remission of Pediatric Acute Megakaryoblastic Leukemia

A Phase I/Pilot Study of CPX-351 [Daunorubicin and Cytarabine Liposome for Injection (Vyxeos®)] for Children, Adolescents and Young Adults with Recurrent or Refractory Acute Leukemia

Final Safety and Efficacy Results from the CPX-351 Early Access Program (EAP) for Older Patients with High-Risk/Secondary Acute Myeloid Leukemia (sAML)

Subanalysis of Patients with Secondary Acute Myeloid Leukemia (sAML) with Refractory Anemia with Excess of Blasts in Transformation (RAEB-t) Enrolled in a Phase 3 Study of CPX-351 Versus Conventional 7+3 Cytarabine and Daunorubicin

Hemophagocytic Lymphohistiocytosis (HLH) in Langerhans Cell Histiocytosis (LCH): A Multicenter Retrospective Descriptional Study

Targeted Inhibition of the MLL Transcriptional Complex By Proteosome Inhibitors Elicits a High Response Rate in Relapsed/Refractory MLL Rearranged Leukemia

Outcomes after Intermediate-Risk Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL) and the Role of Allogeneic Stem Cell Transplantation (SCT): A Report from Children's Oncology Group (COG) AALL0433

Clinical and Laboratory Factors Influencing The Probability Of Complete Remission In AML Patients With Positive Day 14 Bone Marrows

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only